Building a Sustainable System for Curative and Gene Therapies

Disruptive thinking and new models to promote and pay for cures

As gene therapies, cell therapies, immunotherapies, and other biopharmaceutical innovations advance in clinical trials, science is closer than ever to making the concept of curative therapies a reality.  Yet the promise of a “cure” raises a number of questions about how healthcare leaders define and incentivize the development of curative therapies, evaluate their differential value, and structure regulatory and reimbursement pathways to ensure efficacy, safety, and access for patients.  The timing is ripe for relevant stakeholders to proactively come together and start driving at answers to the question: how can we shape a healthcare system that promotes and pays for cures?  Tapestry is currently exploring the development of a multi-stakeholder initiative designed to engage relevant decision-makers and develop pragmatic pilots and models on this topic. 

Recent efforts include:

Workshop on new financing structures for transformative therapies – co-organized by Tapestry Networks, the MIT Laboratory for Financial Engineering and Dana-Farber Cancer Institute
On October 14, 2016, a select group of biotechnology and drug developers, academics, financiers, economists, providers and payers convened in Cambridge, MA to discuss how innovative financing could help expand patient access to transformative therapies in the United States. The organizers sought to channel the cross-sector expertise present to address critical questions, including: How do we get transformative therapies to patients faster and cheaper while incentivizing the development of future transformative therapies? Who pays in the short and long-term: taxpayers, consumers or payers? Can financial engineering help make paying for transformative therapies, especially those that are curative in nature, more sustainable?  Learn more 

Engaging stakeholders & building pragmatic models to sustainably support curative therapies

In a series of discussions conducted in late 2015 - 2016, leaders from biopharmaceutical manufacturers, public and private payers, patient advocacy organizations and individual economists, financiers and subject matter experts shared their views with Tapestry on the value of curative therapies and how best to manage their delivery within the U.S. healthcare system.  These stakeholders also offered feedback on policy barriers and constraints, innovative payment models and paths forward.  Learn more.

For more information contact Lindee Goh.



Copyright © 2017 Tapestry Networks, Inc.   |   Privacy Policy & Cookies   |   Terms of Use   |   Design and development by RainCastle Communications.